Welcome to our dedicated page for Design Therapeutics news (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics stock.
Design Therapeutics, Inc. reports news about its clinical-stage biotechnology business and its GeneTAC® platform for serious degenerative genetic diseases. The company develops gene targeted chimera small molecules designed to modulate expression of disease-causing genes, with programs that include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type 1, and a Huntington’s disease program.
Recurring updates cover financial results, cash resources for pipeline execution, clinical program progress, regulatory clearances, preclinical development, investor conference participation, and board or committee changes. Company announcements frequently connect portfolio milestones with the underlying GeneTAC approach and the therapeutic areas addressed by its genomic medicine programs.
Design Therapeutics, Inc. (Nasdaq: DSGN) has announced promising preclinical results for its GeneTAC™ small molecule, DT-168, aimed at treating Fuchs endothelial corneal dystrophy (FECD). The eye drops reduced nuclear foci and improved mis-splicing in patient-derived corneal endothelial cells. Advanced FECD cases require surgeries like corneal transplants, and no disease-modifying therapies are currently available. DT-168 targets CTG repeat expansions in the TCF4 gene, marking its potential as a disease-modifying treatment. The company is set to submit an Investigational New Drug application for DT-168 in the second half of 2023, indicating a significant step in the therapeutic development process.
Design Therapeutics, Inc. (Nasdaq: DSGN) reported advancements across its pipeline in gene therapies during its fourth quarter and full-year 2022 earnings. The company is progressing in its Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich ataxia, with initial results expected mid-2023. Financially, Design Therapeutics maintains a strong position with $330.4 million in cash and securities, ensuring operations through 2025. R&D expenses were $48.6 million for 2022, contributing to a net loss of $63.3 million. Upcoming milestones include IND submissions for DT-168 and DM1 programs, aiming for clinical development over the next two years.
Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology firm focusing on treatments for degenerative genetic diseases, announced that CEO João Siffert will engage in a fireside chat during the SVB Securities Virtual Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET. This event will be accessible via a live webcast on the company’s website and will be archived for 30 days. Design Therapeutics is pioneering GeneTAC™ therapy aimed at modifying disease-causing gene expressions, currently testing its lead candidate DT-216 for Friedreich ataxia, alongside other programs targeting various genetic disorders.
Design Therapeutics (Nasdaq: DSGN) announced progress in its GeneTAC™ portfolio, including promising results for DT-216 in a Phase 1 trial for Friedreich ataxia (FA). The therapy demonstrated a >2-fold increase in frataxin mRNA, indicating effective gene transcription restoration. DT-216 was well-tolerated with no serious adverse events reported. The company also introduced DT-168 for treating Fuchs endothelial corneal dystrophy, with an IND submission expected in 2023, and aims for an IND for myotonic dystrophy type-1 in 2024.
Design Therapeutics (DSGN) reported significant progress in its clinical pipeline, particularly with DT-216 targeting Friedreich ataxia (FA). Initial data from the single-ascending dose trial is expected in December 2022, while the multiple-ascending dose trial has commenced, aiming for completion by mid-2023. The company, with a solid cash position of $344.2 million, continues to advance its GeneTAC™ platform across multiple diseases. Third-quarter financials show R&D expenses of $14.3 million and a net loss of $17.7 million.
Design Therapeutics is advancing its Friedreich ataxia (FA) treatment, DT-216, as it prepares to report initial Phase 1 trial data in Q4 2022. The company presented promising preclinical findings at the International Congress for Ataxia Research, indicating DT-216's potential to restore frataxin (FXN) gene expression and improve mitochondrial function. Significant results include a 10-fold increase in FXN mRNA in patient-derived cells and restored FXN protein levels in FA neurons. Design aims to share safety and pharmacokinetics data from the trial soon.
Design Therapeutics, Inc. (Nasdaq: DSGN) announced that its CEO, João Siffert, M.D., and COO, Sean Jeffries, Ph.D., will participate in a fireside chat at the 2022 Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast will be available on the investor section of the company's website and archived for 30 days. Design Therapeutics focuses on developing innovative therapies using its GeneTAC™ platform to treat degenerative genetic diseases, with lead programs targeting Friedreich ataxia and myotonic dystrophy type-1.
Design Therapeutics, Inc. (Nasdaq: DSGN) reported a net loss of $15 million and R&D expenses of $11.3 million for Q2 2022. With cash and securities totaling $359.4 million, the company maintains a solid financial position to support its multi-year operational plan. Upcoming milestones include initial data from the Phase 1 trial of DT-216 for Friedreich ataxia expected in Q4 2022, while clinical development for the treatment of myotonic dystrophy type-1 is anticipated in 2023. The company also advances its research on Fuchs endothelial corneal dystrophy.
Design Therapeutics, a clinical-stage biotechnology company focused on serious genetic diseases, announced that CEO João Siffert and COO Sean Jeffries will participate in a fireside chat at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 10, 2022, at 10:20 a.m. ET. A live webcast will be accessible on the company's investor website, with an archive available for 30 days post-event.
Design's GeneTAC™ platform aims to develop therapies addressing genetic disorders like Friedreich ataxia and myotonic dystrophy type-1, targeting disease-causing genes.
Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology firm focused on serious degenerative genetic diseases, announced that CEO João Siffert will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 8:30 a.m. ET in New York City. A live webcast will be available on their investor website, archived for 30 days post-presentation. The company is known for its GeneTAC™ technology aimed at targeting genes responsible for diseases like Friedreich ataxia and myotonic dystrophy type-1.